At a glance
This grant funds exploratory bioengineering research to test new capabilities or improvements for basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility. It uses the NIH R21 grant mechanism and does not allow clinical trials. Eligible applicants include U.S. and non-U.S. organizations such as universities, nonprofits, for-profits, governments, tribes, and foreign organizations, and foreign components of U.S. organizations are allowed. The total direct cost budget for the two-year project period may not exceed $275,000, with no more than $200,000 in any single year, and the program did not state a required cost share. The number of awards depends on NIH appropriations and the quality of applications.
What it funds
Official description from grants.gov
Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.
Who can apply
- City or township governments
- County governments
- For-profit organizations other than small businesses
- Independent school districts
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Others
- Private institutions of higher education
- Public and State controlled institutions of higher education
- Public housing authorities / Indian housing authorities
- Small businesses
- Special district governments
- State governments